Supported by an educational grants from Novo Nordisk Pharmaceuticals.
To address the cardiovascular (CV) morbidity and mortality risks associated with Type 2 Diabetes Mellitus (T2DM), national guidelines now recommend the use of antidiabetic agents that have shown improvement in CV outcomes in clinical trials, including GLP-1 Receptor Agonists (RAs). Despite the benefits of these agents to patients with T2DM, recent data indicate a nationwide shortage in endocrinologists and geographically-related barriers to care may threaten the progress these agents have made in diabetes management. To meet the needs of patients with T2DM, the role of family practitioners (FPs) has expanded to fill the demand; however, FPs require education on the place of GLP-1 RAs in the management of diabetes, including pharmacokinetic/pharmacodynamic mechanisms, safety and efficacy data, Cardiovascular Outcome Trial (CVOT) outcomes, and patient satisfaction and adherence to fully embrace this evolving role. The extension of antidiabetic therapy beyond glycemic control has led to a paradigm shift in the management of T2DM. As a result, FPs must be prepared to take on a larger role in patient care. This activity will provide knowledge to address these educational needs among primarycare providers (PCPs), and application of this knowledge will improve outcomes for patients with T2DM.
This educational initiative has been designed for family physicians, involved in the diagnosis and management of T2DM.
Upon completion of this educational activity, participants should be able to:
Explain geographic trends in access to endocrinologists and define the critical role of PCPs in the management of T2DM
Compare the underlying pathophysiological mechanisms and pharmacokinetic/pharmacodynamic profiles for currently available and emerging GLP-1 RA agents
Evaluate updated guideline recommendations and the clinical trial data on the efficacy and safety of specific GLP-1 RAs, in addition to recent CVOT, patient satisfaction, and adherence data
Identify common provider and patient-related barriers so that GLP-1 RAs can be introduced to more effectively control glucose, improve cardiometabolic risk factors, and increase patient satisfaction and adherence
Describe the optimal use of GLP-1 RAs in the context of practice-based clinical scenarios
Conflict Of Interest Disclosure Policy
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education is committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.
The faculty/planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity.
Vivian A. Fonseca, MD, FRCP Professor of Medicine and Pharmacology Tullis–Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Center New Orleans, Louisiana
Dr. Fonseca discloses the following: Consulting Fees: Abbott; Asahi; AstraZeneca Pharmaceuticals LP; Lilly; Intarcia; Novo Nordisk Pharmaceuticals; Sanofi US; Takeda Pharmaceuticals U.S.A., Inc. Contracted Research: Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc. Ownership Interest: Amgen; BRAVO4Health; Insulin Algorithms; Mircobiome Technologies
Richard E. Pratley, MD Director Florida Hospital Diabetes Institute Senior Scientist Translational Research Institute for Metabolism and Diabetes Orlando, Florida
Dr. Pratley discloses the following: Consulting Fees: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Glytec, LLC; Janssen Scientific Affairs, LLC; Ligand Pharmaceuticals, Inc.; Lilly; Merck; Mundipharma; Novo Nordisk Pharmaceuticals; Pfizer; Sanofi US Speakers Bureau: Novo Nordisk Pharmaceuticals Contracted Research: Lexicon Pharmaceuticals; Ligand Pharmaceuticals, Inc.; Lilly; Merck; Novo Nordisk Pharmaceuticals; Sanofi US
Accredited Provider Disclosure
Patima Tanapat hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
AMA PRA Category 1 Credit(s)TM
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education and Sanofi Genzyme and Regeneron Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
There are no fees for participating and receiving CME credit for this activity. During the period of September 27, 2019 through September 27, 2020, participants must:
Read the learning objectives and faculty disclosures
Complete the pre-test
Study the educational activity
Complete the post-test and the evaluation form
A certificate will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher. Please proceed with the activity until you have successfully passed the post-test, completed the evaluation and received a digital copy of your credit certificate. Pharmacists much check the CPE monitor for credits within 60 days of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc., at (855) 835-4004 or firstname.lastname@example.org.